Communiqués Acelyrin, Inc.

Actions

SLRN

US00445A1007

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 20/05/2025			Varia. 5j.	Varia. 1 janv.
2,270 ^USD	+1,79%		-.--%	-

21/05/25	Alumis Inc. (NasdaqGS : ALMS) a finalisé l'acquisition d'Acelyrin, Inc. (NasdaqGS : SLRN) auprès d'un groupe d'actionnaires.	CI
21/05/25	Alumis et Acelyrin finalisent leur fusion	MT

Communiqués

13/05/25	Alumis Stockholders Approve Merger with ACELYRIN	AQ
13/05/25	ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases	GL
06/05/25	Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis	GL
01/05/25	ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis	GL
21/04/25	Alumis and ACELYRIN Announce Amended Merger Agreement	GL
21/04/25	Alumis and ACELYRIN Announce Amended Merger Agreement	AQ
16/04/25	ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN	BU
13/03/25	ACELYRIN Adopts Limited-Duration Stockholder Rights Plan	AQ
13/03/25	ACELYRIN Adopts Limited-Duration Stockholder Rights Plan	GL
04/03/25	ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger	GL
04/03/25	Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger	AQ
04/03/25	ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger	GL
21/02/25	ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences	GL
10/02/25	ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN	BU
06/02/25	Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases	GL
06/01/25	ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease	GL
03/01/25	ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab	GL
10/12/24	Affibody’s Licensee ACELYRIN Announces Top-line Results for Izokibep in Uveitis	AQ
10/12/24	ACELYRIN : Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis Form 8 K	PU
10/12/24	ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis	GL
13/11/24	ACELYRIN : Reports Third Quarter 2024 Financial Results and Recent Highlights Form 8 K	PU
13/11/24	Acelyrin : INDEPENDENT AUDITOR'S REPORT Form 8 K	PU
13/11/24	ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights	GL
06/11/24	ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024	GL
16/10/24	ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease	AQ